ProCE Banner Activity

Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma

Podcast Episodes
In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss the key data on adjuvant and neoadjuvant therapy and review current and emerging treatment options for metastatic disease.

Released: September 28, 2021

Expiration: September 27, 2022

No longer available for credit.

Share

Faculty

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Hussein Tawbi

Hussein Tawbi, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Jeffrey S. Weber, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Moderna, Novartis, and Pfizer.

Faculty Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD, has disclosed that she has received consulting fees from BluePath Solutions, Iovance, Nanobiotix, Novartis, Pfizer, and Shanghai Jo’Ann Medical Technology.

Hussein Tawbi, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Hussein Tawbi, MD, PhD has disclosed that he has received consulting fees from Bristol-Myers Squibb, Eisai, Genentech/Roche, Iovance, Karyopharm, Merck, Novartis, and Pfizer and funds for research support (paid to his institution) from Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, and Novartis.